This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Valeant Pharmaceuticals International, Inc.
Drug Names(s): verteporfin
Description: Visudyne is a light activated drug that involves two processes. Visudyne (verteporfin) is injected into the eye and is then activated by red light laser. Once verteporfin is activated by light in the presence of oxygen, reactive oxygen radicals are generated which damages the neovascular endothelium, destroying the abnormal blood vessels.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
QLT and CIBA Vision
In 1995, CIBA Vision and QLT entered into a global agreement to co-develop photodynamic therapy for eye diseases.
Ciba-Geigy and Sandoz
In 1996, Ciba-Geigy merged with Sandoz to form Novartis, and CIBA Vision became the eye care unit of Novartis.
QLT and Novartis
Visudyne is manufactured by QLT and sold by Novartis under the terms of a co-development, manufacturing and commercialization agreement with Novartis.
In October 2009, QLT announced that it restructured its agreement with Novartis Pharma to simplify the relationship, which takes effect January 1, 2010.
Under the Amended and Restated PDT Product Development, Manufacturing and Distribution Agreement, QLT will have exclusive U.S. sales and marketing rights to Visudyne, including rights to all end-user revenue derived from Visudyne sales in the U.S. Novartis will have marketing and sales rights in all...See full deal structure in Biomedtracker
Partners: Novartis AG QLT, Inc.
Additional information available to subscribers only: